Insider Transactions in Q1 2025 at An2 Therapeutics, Inc. (ANTX)
Insider Transaction List (Q1 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 26
2025
|
Lucy Day Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
46,500
+37.0%
|
-
|
|
Feb 26
2025
|
Sanjay Chanda Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,250
+38.56%
|
-
|
|
Feb 26
2025
|
Eric Easom Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
145,250
+37.09%
|
-
|
|
Feb 26
2025
|
Joshua M Eizen |
BUY
Grant, award, or other acquisition
|
Direct |
58,500
+25.04%
|
-
|
|
Feb 26
2025
|
Stephen David Prior Chief Strategy Officer |
BUY
Grant, award, or other acquisition
|
Direct |
28,000
+31.35%
|
-
|
|
Jan 03
2025
|
Sanjay Chanda Chief Development Officer |
SELL
Open market or private sale
|
Direct |
2,957
-9.02%
|
$2,957
$1.34 P/Share
|
|
Jan 03
2025
|
Lucy Day Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,957
-8.3%
|
$2,957
$1.34 P/Share
|
|
Jan 03
2025
|
Joshua M Eizen |
SELL
Open market or private sale
|
Direct |
9,663
-7.65%
|
$9,663
$1.34 P/Share
|
|
Jan 03
2025
|
Stephen David Prior Chief Strategy Officer |
SELL
Open market or private sale
|
Direct |
2,029
-5.74%
|
$2,029
$1.34 P/Share
|